Stocks · News reference
Xenon Pharmaceuticals reported positive Phase 1 study results and new preclinical data for its acute pain candidates, XEN1701 and XEN1120, supporting their advancement into Phase 2 proof-of-concept studies.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Xenon Pharmaceuticals (NASDAQ:XENE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.
Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.